Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 18, 2022

BUY
$131.8 - $202.24 $98,981 - $151,882
751 Added 6.2%
12,855 $1.73 Million
Q2 2022

Aug 15, 2022

BUY
$121.11 - $216.05 $329,903 - $588,520
2,724 Added 29.04%
12,104 $1.96 Million
Q1 2022

May 16, 2022

SELL
$146.52 - $269.56 $30,183 - $55,529
-206 Reduced 2.15%
9,380 $1.77 Million
Q4 2021

Feb 15, 2022

BUY
$248.56 - $389.34 $1.62 Million - $2.54 Million
6,524 Added 213.06%
9,586 $2.6 Million
Q2 2021

Aug 16, 2021

BUY
$292.75 - $367.01 $896,400 - $1.12 Million
3,062 New
3,062 $1.05 Million
Q4 2020

Feb 16, 2021

SELL
$221.31 - $316.61 $13.1 Million - $18.8 Million
-59,413 Closed
0 $0
Q3 2020

Nov 17, 2020

BUY
$189.18 - $286.44 $387,440 - $586,629
2,048 Added 3.57%
59,413 $17 Million
Q2 2020

Aug 17, 2020

BUY
$123.9 - $195.41 $285,093 - $449,638
2,301 Added 4.18%
57,365 $10.8 Million
Q1 2020

May 13, 2020

BUY
$121.84 - $173.19 $483,948 - $687,910
3,972 Added 7.77%
55,064 $6.78 Million
Q4 2019

Feb 14, 2020

BUY
$115.78 - $208.34 $264,788 - $476,473
2,287 Added 4.69%
51,092 $8.47 Million
Q3 2019

Nov 15, 2019

BUY
$120.61 - $148.29 $76,225 - $93,719
632 Added 1.31%
48,805 $5.98 Million
Q2 2019

Aug 14, 2019

BUY
$113.99 - $146.86 $1.71 Million - $2.21 Million
15,041 Added 45.4%
48,173 $5.97 Million
Q1 2019

May 09, 2019

SELL
$122.82 - $151.83 $2,579 - $3,188
-21 Reduced 0.06%
33,132 $4.37 Million
Q4 2018

Feb 13, 2019

BUY
$107.01 - $175.15 $3.55 Million - $5.81 Million
33,153 New
33,153 $4.65 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.7B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.